Tvardi Therapeutics, Inc. TVRD
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -81.56%
- 1 year
- -82.99%
- Open
- 0.8677
- Prev close
- 0.863
- Mkt cap
- 10.58M
- Vol
- 154.88K
- Avg vol
- 185.66K
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7751
- High
- 0.9284
News
-
1 week ago benzinga.com
Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8
Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
2 weeks ago globenewswire.com
Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
1 month ago defenseworld.net
Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC)
Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
-
1 month ago benzinga.com
Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and…
1 month ago globenewswire.com
New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)
In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and…
2 months ago globenewswire.com
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…
2 months ago seekingalpha.com
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2…
-
2 months ago benzinga.com
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of…
2 months ago globenewswire.com
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations
-
2 months ago benzinga.com
Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC
Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to
2 months ago globenewswire.com
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral,…
-
3 months ago benzinga.com
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.
3 months ago globenewswire.com
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…
3 months ago zacks.com
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
3 months ago benzinga.com
Why Is Tvardi Therapeutics Stock Falling Thursday?
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
-
3 months ago benzinga.com
Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target
Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perform to Outperform and announces $10 price target.
3 months ago seekingalpha.com
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
3 months ago benzinga.com
Why Is Tvardi Therapeutics Stock Gaining Tuesday?
Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen STAT3 inhibitor, TTI-109. Read more.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
-
3 months ago benzinga.com
BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
-
3 months ago benzinga.com
Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)…
3 months ago globenewswire.com
Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
4 months ago benzinga.com
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
4 months ago benzinga.com
This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Analysts think CBRS stock is a buy.
-
4 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $9.
5 months ago globenewswire.com
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…
-
5 months ago benzinga.com
Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 77.33 percent increase over losses of…
5 months ago globenewswire.com
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in…
-
6 months ago benzinga.com
Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
6 months ago defenseworld.net
Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) PT at $55.50
Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company,…
-
6 months ago benzinga.com
Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
7 months ago globenewswire.com
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…
-
7 months ago benzinga.com
Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4
Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and lowers the price target from $5 to $4.
-
7 months ago benzinga.com
Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
-
7 months ago benzinga.com
Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 15.38 percent. This is a 84.21 percent increase over losses…
7 months ago globenewswire.com
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in…
8 months ago defenseworld.net
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average PT from Analysts
Shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings…
9 months ago globenewswire.com
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session